Balcinrenone vs Finerenone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Mineralocorticoid receptor · full Heart Failure pipeline
Balcinrenone
Developed by AstraZeneca
NCT04595370 · Phase 2 · completed
The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.
Next expected readout: April 2027 · NCT06307652 (registry estimate)
No aligned efficacy figure on record for this race.
Finerenone · Kerendia
Marketed by Bayer
NCT04435626 · Phase 3 · completed
The trial randomized 6,016 participants to finerenone or matching placebo and masked participants, care providers, investigators, and outcome assessors. Its hard clinical primary endpoint was met: finerenone produced fewer cardiovascular death and recurrent heart-failure events than placebo, with a rate ratio of 0.84 (95% CI 0.74–0.95; p=0.0072).
Next expected readout: September 2027 · NCT07830940 (registry estimate)
Reported efficacy
Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months); Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events (From randomization up until the end of study, with an average study duration of 32 months): Finerenone (BAY94-8862) 1083 events | Placebo 1283 events (met)
Result source: NCT04435626
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Balcinrenone | Finerenone |
|---|---|---|
| CV death or HF hospitalisation | —Trial running · NCT06307652 | —Trial running · NCT07270367 |
| HF hospitalisation | —Trial running · NCT06307652 | —Trial running · NCT07270367 |
| CV death | —Trial running · NCT06307652 | —Trial running · NCT07270367 |
| KCCQ clinical summary, change | —Trial running · NCT06307652 | 21.3 vs 24.3vs EplerenoneNCT018072219 other results
|
CV death or HF hospitalisation
- Balcinrenone
- —Trial running · NCT06307652
- Finerenone
- —Trial running · NCT07270367
HF hospitalisation
- Balcinrenone
- —Trial running · NCT06307652
- Finerenone
- —Trial running · NCT07270367
CV death
- Balcinrenone
- —Trial running · NCT06307652
- Finerenone
- —Trial running · NCT07270367
KCCQ clinical summary, change
- Balcinrenone
- —Trial running · NCT06307652
- Finerenone
- 21.3 vs 24.3vs EplerenoneNCT01807221
9 other results
- 24.5 vs 24.3 NCT01807221
- 29.3 vs 24.3 NCT01807221
- 28.3 vs 24.3 NCT01807221
- 22.2 vs 24.3 NCT01807221
- 18.2 vs 20.5 NCT01807221
- 19.3 vs 20.5 NCT01807221
- 23 vs 20.5 NCT01807221
- 24.9 vs 20.5 NCT01807221
- 20.6 vs 20.5 NCT01807221
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Balcinrenone: 4 of 4 rows · Finerenone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Balcinrenone | Finerenone |
|---|---|---|
| Dropout rate | 14.3%150 mga NCT04595370 · Phase 2 · registry result, not featured evidence show 3 more results25%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination | 0.5%b NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3 show 6 more results21.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 24.8%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 30.1%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 26.1%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 27.2%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 14.3%150 mga NCT04595370 · Phase 2 · registry result, not featured evidence show 3 more results8.3%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination | —b NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3 show 6 more results10.6%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 15.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 14.8%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%150 mga NCT04595370 · Phase 2 · registry result, not featured evidence show 3 more results5.9%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination | 38.7%b NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3 show 6 more results27.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 35%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 28.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 31.1%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 41.9%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 150 mga chronic kidney disease 16.7% (placebo 0%) gingival recession 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence show 3 more results150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination | b covid-19 9.8% (placebo 9.9%) hyperkalaemia 8.4% (placebo 3.6%) hypotension 7% (placebo 4.3%) NCT04435626 · Phase 3 · monotherapy · Heart Failure · phase 3 show 5 more results10-20 mg OD hypokalaemia 8.3% renal impairment 4.7% cardiac failure 4.1% NCT01807221 · Phase 2 · registry result, not featured evidence 15-20 mg OD hypokalaemia 10.4% cardiac failure 6.1% dyspnoea 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 5-10 mg OD hypokalaemia 12.9% hypotension 6.7% cardiac failure 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 7.5-15 mg OD hypokalaemia 9% hypotension 6.6% diarrhoea 6% NCT01807221 · Phase 2 · registry result, not featured evidence 2.5-5 mg OD hypokalaemia 11.6% cardiac failure 8.1% dyspnoea 7% NCT01807221 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Balcinrenone
show 7 more results
show 3 more results
Finerenone
show 4 more results
show 14 more results
show 4 more results
show 14 more results
show 4 more results
show 9 more results
show 9 more results
show 4 more results
Chronic Kidney Disease
Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline
Balcinrenone
Developed by AstraZeneca
NCT04595370 · Phase 2 · completed
The trial was randomized and quadruple-blind, with dapagliflozin as the active comparator, but the primary endpoint was the surrogate biomarker UACR rather than a clinical heart-failure or kidney outcome. The primary comparison was not statistically significant, and the study had relatively small analyzed groups after placebo and AZD9977 monotherapy arms were removed early.
Next expected readout: July 2030 · NCT07624305 (registry estimate)
Reported efficacy
Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): Percent Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) at Week 12 (Baseline (Day 1) to Week 12): AZD9977 15 mg + Dapagliflozin 10 mg -56.391% (95% CI -71.528--33.207) vs AZD9977 50 mg + Dapagliflozin 10 mg -42.085% (95% CI -64.174--6.376) vs AZD9977 150 mg + Dapagliflozin 10 mg -58.047% (95% CI -73.560--33.430) vs AZD9977 150 mg -45.01% (95% CI NA-NA) vs Dapagliflozin 10 mg -34.318% (95% CI -58.204-3.220) vs Placebo 230.32% (95% CI NA-NA); p=0.3645 (AZD9977 15 mg + Dapagliflozin 10 mg vs AZD9977 50 mg + Dapagliflozin 10 mg vs AZD9977 150 mg + Dapagliflozin 10 mg vs Dapagliflozin 10 mg) (missed)
Result source: NCT04595370
Finerenone · Kerendia
Marketed by Bayer
NCT02540993 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and large, with 5,734 participants randomized nearly equally between finerenone and placebo. Its hard clinical kidney endpoint was met: 504 participants receiving finerenone versus 600 receiving placebo experienced the primary outcome, with a statistically significant hazard ratio of 0.825 (p=0.0014).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Mean rate of change as measured by the total slope of eGFR from baseline to Month-32. (From baseline to month 32): Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001) (met)
Result source: NCT05047263
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Balcinrenone | Finerenone |
|---|---|---|
| Kidney composite outcome | —Trial running · NCT07624305 | —Not posted · NCT05047263 |
| UACR, % change | -58.0% vs 230.3%−288.4 vs placeboNCT045953707 other results
| —Not posted · NCT05047263 |
| eGFR slope | —Trial running · NCT07624305 | —Not posted · NCT05047263 |
| Haemoglobin, change | —Trial running · NCT07624305 | —Not posted · NCT05047263 |
Kidney composite outcome
- Balcinrenone
- —Trial running · NCT07624305
- Finerenone
- —Not posted · NCT05047263
UACR, % change
- Balcinrenone
- -58.0% vs 230.3%−288.4 vs placeboNCT04595370
7 other results
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -45.0% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -45.0% vs 230.3% NCT04595370
- Finerenone
- —Not posted · NCT05047263
eGFR slope
- Balcinrenone
- —Trial running · NCT07624305
- Finerenone
- —Not posted · NCT05047263
Haemoglobin, change
- Balcinrenone
- —Trial running · NCT07624305
- Finerenone
- —Not posted · NCT05047263
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Balcinrenone: 4 of 4 rows · Finerenone: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Balcinrenone | Finerenone |
|---|---|---|
| Dropout rate | 14.3%150 mga NCT04595370 · Phase 2 show 3 more results25%150 mg + 10 mg NCT04595370 · Phase 2 · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · combination | 1.5%b NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results—Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 1% NCT05013008 · Phase 2 · registry result, not featured evidence 21.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 24.8%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 30.1%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 26.1%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 27.2%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 14.3%150 mga NCT04595370 · Phase 2 show 3 more results8.3%150 mg + 10 mg NCT04595370 · Phase 2 · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · combination | —b NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results—Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence — NCT05013008 · Phase 2 · registry result, not featured evidence 10.6%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 15.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 14.8%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%150 mga NCT04595370 · Phase 2 show 3 more results5.9%150 mg + 10 mg NCT04595370 · Phase 2 · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · combination | 31.9%b NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 6.1%Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence — NCT05013008 · Phase 2 · registry result, not featured evidence 27.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 35%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 28.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 31.1%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 41.9%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 150 mga chronic kidney disease 16.7% (placebo 0%) gingival recession 16.7% (placebo 0%) headache 16.7% (placebo 0%) NCT04595370 · Phase 2 show 3 more results150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · combination | b hyperkalaemia 14.9% (placebo 7.5%) nasopharyngitis 8.5% (placebo 8.8%) anaemia 7.1% (placebo 6.3%) NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 7 more resultshyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination hyperkalaemia 10.2% glomerular filtration rate decreased 4.2% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence 10-20 mg OD hypokalaemia 8.3% renal impairment 4.7% cardiac failure 4.1% NCT01807221 · Phase 2 · registry result, not featured evidence 15-20 mg OD hypokalaemia 10.4% cardiac failure 6.1% dyspnoea 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 5-10 mg OD hypokalaemia 12.9% hypotension 6.7% cardiac failure 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 7.5-15 mg OD hypokalaemia 9% hypotension 6.6% diarrhoea 6% NCT01807221 · Phase 2 · registry result, not featured evidence 2.5-5 mg OD hypokalaemia 11.6% cardiac failure 8.1% dyspnoea 7% NCT01807221 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 10 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Balcinrenone
show 7 more results
show 3 more results
Finerenone
show 3 more results
show 4 more results
show 14 more results
show 4 more results
show 9 more results
show 9 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Balcinrenone's landscape · Finerenone's landscape